Humoral immune response to COVID‐19 vaccination in diabetes is age‐dependent but independent of type of diabetes and glycaemic control: The prospective COVAC‐DM cohort study. Issue 5 (24th January 2022)

• Record Type: Journal Article
• Authors: Sourij, Caren; Tripolt, Norbert J.; Aziz, Faisal; Aberer, Felix; Forstner, Patrick; Obermayer, Anna M.; Kojzar, Harald; Kleinhappl, Barbara; Pferschy, Peter N.; Mader, Julia K.; Cvirn, Gerhard; Goswami, Nandu; Wachsmuth, Nadine; Eckstein, Max L.; Müller, Alexander; Abbas, Farah; Lenz, Jacqueline; Steinberger, Michaela; Knoll, Lisa; Krause, Robert; Stradner, Martin; Schlenke, Peter; Sareban, Nazanin; Prietl, Barbara; Kaser, Susanne; Moser, Othmar; Steinmetz, Ivo; Sourij, Harald
• Is Part Of: Diabetes, obesity & metabolism. Volume 24:Issue 5(2022)
• Page Start: 849
• Page End: 858
• Publication Date: 2022-01-24
• Subjects: COVID‐19 -- observational study -- type 1 diabetes -- type 2 diabetes; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14643
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Aims: To investigate the seroconversion following first and second COVID‐19 vaccination in people with type 1 and type 2 diabetes in relation to glycaemic control prior to vaccination and to analyse the response in comparison to individuals without diabetes. Materials and methods: This prospective, multicentre cohort study analysed people with type 1 and type 2 diabetes and a glycated haemoglobin level ≤58 mmol/mol (7.5%) or >58 mmol/mol (7.5%), respectively, and healthy controls. Roche's Elecsys anti‐SARS‐CoV‐2 S immunoassay targeting the receptor‐binding domain was used to quantify anti‐spike protein antibodies 7 to 14 days after the first and 14 to 21 days after the second vaccination. Results: A total of 86 healthy controls were enrolled in the study, as well as 161 participants with diabetes, of whom 150 (75 with type 1 diabetes and 75 with type 2 diabetes) were eligible for the analysis. After the first vaccination, only 52.7% of participants in the type 1 diabetes group and 48.0% of those in the type 2 diabetes group showed antibody levels above the cut‐off for positivity. Antibody levels after the second vaccination were similar in participants with type 1 diabetes, participants with type 2 diabetes and healthy controls after adjusting for age, sex and multiple testing ( P > 0.05). Age ( r = −0.45, P < 0.001) and glomerular filtration rate ( r = 0.28, P = 0.001) were significantly associated with antibody response. Conclusions: Anti‐SARS‐CoV‐2 S receptor‐binding domain antibody levels after the second vaccination were comparable in healthy controls and in participants with type 1 and type 2 diabetes, irrespective of glycaemic control. Age and renal function correlated significantly with the extent of antibody levels.